📰 Double Blinded News
Double Blinded News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Double Blinded. Real-time updates on events, politics, business and more.
May 29, 2023
MyJournals.org - Science - Pharmaceuticals, Vol. 16, Pages 799: Phase II, Double-Blinded, Randomized, Placebo-Controlled Clinical Trial Investigating the Efficacy of Mebendazole in the Management of Symptomatic COVID-19 Patients (Pharmaceuticals)
November 15, 2022
/PRNewswire/ -- Chronic obstructive pulmonary disease is a chronic lung disease that prevents airflow from the lungs. The rising incidence of COPD is one...
November 15, 2022
FinancialNewsMedia.com News Commentary PALM BEACH, Fla, Nov. 15, 2022 /PRNewswire/ -- Chronic obstructive pulmonary disease is a chronic lung disease that prevents airflow from the lungs.
November 15, 2022
Clinical Trial UpdateDAVIE, FL / ACCESSWIRE / November 15, 2022 / Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company focused on the development of innovative
September 22, 2022
-- CK0803 are neurotropic, allogeneic, umbilical cord blood derived T regulatory (Treg) cells -- CK0803 represents the company's fifth program to receive IND Clearance utilizing Cellenkos' proprietary CRANEtechnology HOUSTON, Sept. 22, 2022 /PRNewswire/ -- Cellenkos, Inc., a clinical stage biotech company that focuses on developing transformative cellular therapeutics for treatment of inflammatory disorders and autoimmune diseases, today announced that the U.S. Food and Drug Administrati...
February 8, 2022
MIAMI, FL / ACCESSWIRE / February 8, 2022 / Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced
February 8, 2022
Organicell And Proxima CRO Set To Open Clinical Trial For Long Hauler COVID-19 Patients PRESS RELEASE Miami, FL Miami -Organicell Regenerative Medicine, Inc. , a... | February 8, 2022
December 29, 2021
MIAMI, FL / ACCESSWIRE / December 29, 2021 / Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, is pleased
October 27, 2021
Abivertinib is an oral capsule (100 mg QD or two 50-mg capsules a day) that potentially reduces cytokine storm associated with acute respiratory distress...
October 27, 2021
Press release content from Globe Newswire. The AP news staff was not involved in its creation.